Fremanezumab: a disease-specific option for the preventive treatment of migraine, including difficult-to-treat migraine

Fremanezumab is a fully humanized monoclonal antibody (IgG2Δa) that targets calcitonin gene-related peptide (CGRP), a key neuropeptide involved in the pathophysiology of migraine. Fremanezumab is approved for quarterly and monthly subcutaneous dosing for the preventive treatment of migraine in adult...

Descripción completa

Detalles Bibliográficos
Autores principales: Friedman, Deborah I., Cohen, Joshua M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Portland Press Ltd. 2020
Materias:
Review Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7487173/
https://www.ncbi.nlm.nih.gov/pubmed/32832978
http://dx.doi.org/10.1042/ETLS20200018

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7487173/
https://www.ncbi.nlm.nih.gov/pubmed/32832978
http://dx.doi.org/10.1042/ETLS20200018

Ejemplares similares